

## Nagrody i wyróżnienia naukowe

rodzaj wyróżnienia/nagrody	rok otrzymania
Zespołowa Nagroda Naukowa im. Tadeusza Browicza Wydziału Lekarskiego Polskiej Akademii Umiejętności	2008
Zespołowa Nagroda Naukowa Wydziału Medycznego Polskiej Akademii Nauk	2005
Zespołowa Nagroda Ministra Zdrowia	1992, 1997, 1999, 2003, 2006, 2007, 2010
Indywidualna Nagroda Naukowa Rektora Akademii Medycznej w Białymstoku	1993, 2001
Zespołowa Nagroda Naukowa Rektora Akademii/Uniwersytetu Medycznego w Białymstoku	1997, 1998, 2002, 2006, 2009, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022
Nagroda Dydaktyczna Rektora Uniwersytetu Medycznego w Białymstoku	2018

## Podręczniki i opracowania akademickie

Redakcja naukowa podręcznika akademickiego Drożdżik M., Kocic I., Pawlak D.: <i>Farmakologia i toksykologia</i> . E Mutschler, MedPharm 2016, wydanie 4
Redakcja naukowa podręcznika akademickiego Bień B., Wojszel ZB., Pawlak D., Wieczorkowska-Tobis K.: <i>Farmakoterapia w geriatrici</i> . Schafer, Liekweg, Eistert MedPharm 2017, wydanie 1
Podręcznik akademicki: <i>Patologia mowy</i> . Redaktor: Tarkowski Z. (rozdział 17) Pawlak D., Kamiński T.: <i>Farmakoterapia zaburzeń mowy</i> . Harmonia 2017, wydanie 1
Pawlak D., Kamiński T.: <i>Pharmacological Basis for Therapy of People Who Stutter – Past, Present and Future</i> . (rozdział 4) książki pod redakcją Tarkowskiego Z.: <i>A new approach to stuttering diagnosis and therapy</i> . Nova Science Publishers, Inc. New York 2017, wydanie 1
Redakcja naukowa podręcznika akademickiego Pawlak D. Sienkiewicz-Oleszkiewicz B.: <i>Farmakologia z elementami toksykologii. Farmakologia ogólna i kliniczna, toksykologia</i> . Tom 1 i 2 E Mutschler, MedPharm 2020, wydanie 1
Pawlak D., Kamiński T.: <i>Afazjologia – organiczne zaburzenia mowy</i> . (rozdział 26) książki pod redakcją Zbigniewa Tarkowskiego: <i>Farmakoterapia zaburzeń mowy u pacjentów neurologicznych – przegląd literatury, aktualne wytyczne oraz perspektywy nowych rozwiązań farmakologicznych</i> . PZWL 2021, wydanie 1

## Wykaz prac opublikowanych w latach 2024-1989

(dane z dnia 2024-01-02 Analiza bibliometryczna publikacji Uniwersytetu Medycznego w Białymstoku <http://212.33.76.61/expertus/new/bib/index.html>)

współczynnik Hirscha (Web of Science) = **28**

IF = **504**

punktacja ministerstwa = **8813**

### 2024 rok

Kwiatkowska I, Hermanowicz JM, Czarnomysy R, Surażyński A, Kowalczyk K, Kałafut J, Przybyszewska-Podstawka A, Bielawski K, Rivero-Müller A, Mojzych M, PAWLAK D.: *Assessment of an anticancer effect of the simultaneous administration of MM-129 and indoximod in the colorectal cancer model*. **Cancers** 2024,16(1), 122 doi.org/10.3390/cancers16010122

Tankiewicz-Kwedlo A, Łobacz T, Kozłowski L, Czartoryska-Arlukowicz B, Koda M, Pawlak K, Czarnomysy R, Borkowska Magdalena J, PAWLAK D.: *ONCOBREAST-TEST is a quick diagnostic, prognostic and predictive method of response to systemic treatment*. **Cancers** 2024, 16(1), 120 doi.org/10.3390/cancers16010120

## 2023 rok

Nowowiejska J, Baran A, Hermanowicz Justyna Magdalena, Sieklucka Beata, PAWLAK D, Flisiak I: *Evaluation of plasma concentrations of galectins-1, 2 and 12 in psoriasis and their clinical implications.* **Biomolecules** 2023, 13 (10), 13 doi: 10.3390/biom13101472. PMID: 37892153

Nowowiejska J, Baran A, Pryczynicz A, Hermanowicz J, Sieklucka B, PAWLAK D, Flisiak I: *Gasdermin E (GSDME) - a new potential marker of psoriasis and its metabolic complications: the first combined study on human serum, urine and tissue.* **Cells** 2023, 12 (17), 11 doi: 10.3390/cells12172149. PMID: 37681881

Pawłowski To, Małyszczak K, PAWLAK D, Ingłot M, Zalewska M, Grzywacz A, Radkowski M, Laskus T, Janocha-Litwin J, Frydecka D: *HTR1A, TPH2, and 5-HTTLPR polymorphisms and their impact on the severity of depressive symptoms and on the concentration of tryptophan catabolites during hepatitis C treatment with pegylated interferon- $\alpha$ 2a and oral ribavirin (PEG-IFN- $\alpha$ 2a/RBV).* **Cells** 2023, 12 (6), 16 doi: 10.3390/cells12060970. PMID: 36980311

Nowowiejska J, Baran A, Hermanowicz J, Sieklucka B, PAWLAK D, Flisiak I: *Tumor necrosis factor (TNF)  $\alpha$ , endothelin (ET) 1 and  $\alpha$ 1-acid glycoprotein (AGP) as potential urine and serum markers of metabolic complications in psoriasis?* **Dermatology and Therapy** 2023, 13 (10), 2217-2227 doi: 10.1007/s13555-023-00992-2. PMID: 37568012

Nowowiejska J, Baran A, Hermanowicz J, Pryczynicz A, Sieklucka B, PAWLAK D, Flisiak I: *Gasdermin D (GSDMD) is upregulated in psoriatic skin - a new potential link in the pathogenesis of psoriasis.* **International Journal of Molecular Sciences** 2023, 24 (17), 12 doi: 10.3390/ijms241713047. PMID: 37685853

Rożkiewicz D, Hermanowicz J, Kwiatkowska I, Krupa A, PAWLAK D: *Bruton's Tyrosine Kinase Inhibitors (BTKIs): review of preclinical studies and evaluation of clinical trials.* **Molecules** 2023, 28 (5), 21 doi: 10.3390/molecules28052400. PMID: 36903645

Nowowiejska J, Baran A, Hermanowicz JM, Pryczynicz A, Sieklucka B, Pawlak D, Flisiak I: *Gasdermin C (GSDMC) is Overexpressed in Psoriatic Tissue and Elevated in Psoriatic Serum: A Potential Marker of Cell Proliferation and Local Hypoxia in Psoriasis?* **Dermatologic Therapy** 2023, ID 7813287 doi.org/10.1155/2023/7813287

Kiluk M, Lewkowicz J, Kowalska I, PAWLAK D, Łagoda K, Tankiewicz-Kwedło A: *Alterations of the kynurenine pathway in patients with type 1 diabetes are associated with metabolic control of diabetes.* **Polskie Archiwum Medycyny Wewnętrznej-Polish Archives of Internal Medicine** 2023, 133 (11), 5 doi: 10.20452/pamw.16581. PMID: 37795878

## 2022 rok

Wesołowski J, Tankiewicz-Kwedło A, PAWLAK D: *Modern immunotherapy in the treatment of triple-negative breast cancer.* **Cancers** 2022, 14 (16), 37 doi: 10.3390/cancers14163860. PMID: 36010854

Nowowiejska J, Baran A, Hermanowicz J, Sieklucka B, Krahel J, Kiluk P, PAWLAK D, Flisiak I: *Fatty acid-binding protein 7 (FABP-7), glutamic acid and neurofilament light chain (NFL) as potential markers of neurodegenerative disorders in psoriatic patients - a pilot study.* **Journal of Clinical Medicine** 2022, 11 (9), 14 doi: 10.3390/jcm11092430. PMID: 35566558

Jakimczuk A, Kałaska B, Kamiński KI, Mikłosz J, Shin-Ichi Y, PAWLAK D, Szczubiałka K, Mogielnicki A: *Monitoring of anticoagulant activity of dabigatran and rivaroxaban in the presence of heparins.* **Journal of Clinical Medicine** 2022, 11 (8), 11 doi: 10.3390/jcm11082236. PMID: 35456329

Baran A, Nowowiejska J, Hermanowicz J, Sieklucka B, Krahel J, Kiluk P, PAWLAK D, Flisiak I: *The potential role of serum tau protein (MAPT), neuronal cell adhesion molecule (NrcAM) and neprilysin (NEP) in neurodegenerative disorders development in psoriasis - preliminary results.* **Journal of Clinical Medicine** 2022, 11 (17), 14 doi: 10.3390/jcm11175044. PMID: 36078974

Massalska M, Ciechowicz M, Kuca-Warnawin E, Burakowski T, Kornatka A, Radzikowska A, PAWLAK D, Muz B, Łoniewska-Lwowska A, Pałucha Aj, Małydyk P, Maśliński W: *Effectiveness of soluble CTLA-4-Fc in the inhibition of bone marrow T-cell activation in context of indoleamine 2,3-dioxygenase (IDO) and CD4<sup>+</sup>Foxp3<sup>+</sup> Treg induction.* **Journal of Inflammation Research** 2022,15, 6813-6829 doi: 10.2147/JIR.S359775. PMID: 36578517

Nowowiejska J, Baran A, Hermanowicz J, Mikłosz J, Kamiński K, Kondraciuk M, Dubatówka Ma, PAWLAK D, Flisiak I: *Angiopoietin-like 4 (ANGPTL4) in patients with psoriasis, lichen planus and vitiligo - a pilot study from the Białystok+ Polish Longitudinal University Study*. **Metabolites** 2022, 12 (9), 7 doi: 10.3390/metabo12090877. PMID: 36144281

Kwiatkowska I, Hermanowicz J, Iwińska Ż, Kowalczyk K, Iwanowska J, PAWLAK D: *Zebrafish - an optimal model in experimental oncology*. **Molecules** 2022, 27 (13), 15 doi: 10.3390/molecules27134223. PMID: 35807468

Ziemińska M, PAWLAK D, Sieklucka B, Chilkwicz K, Pawlak K: *Vitamin K-dependent carboxylation of osteocalcin in bone - ally or adversary of bone mineral status in rats with experimental chronic kidney disease?* **Nutrients** 2022, 14 (19), 18 doi: 10.3390/nu14194082. PMID: 36235734

Wesołowski J, Tankiewicz-Kwedło A, PAWLAK D: *Współczesna immunoterapia w leczeniu Potrójnie Negatywnego Raka Piersi*. **Wydawnictwo Naukowe TYGIEL** 2022 s. 231-247

Kańska B, Mikłosz J, Świętoń J, Jakimczuk A, PAWLAK D, Mogielnicki A: *The effect of ChAdOx1 nCov-19 vaccine on arterial thrombosis development and platelet aggregation in female rats*. **Vaccine** 2022, 40 (13), 1996-2002 doi: 10.1016/j.vaccine.2022.02.037. PMID: 35183388

## 2021 rok

Rzepka Z, Rok J, Maszczyk M, Beberok A, Hermanowicz J, PAWLAK D, Gryko D, Wrześniok D: *Response of human glioblastoma cells to vitamin B12 deficiency: a study using the non-toxic cobalamin antagonist*. **Biology** 2021, 10 (1), 15 doi: 10.3390/biology10010069. PMID: 33478021

Hermanowicz J, Pawlak K, Sieklucka B, Czarnomysy R, Kwiatkowska I, Kazberuk A, Surażyński A, Mojzych M, PAWLAK D: *MM-129 as a novel inhibitor targeting PI3K/AKT/mTOR and PD-L1 in colorectal cancer*. **Cancers** 2021,13 (13), 23 doi: 10.3390/cancers13133203. PMID: 34206937

Kwiatkowska I, Hermanowicz J, Przybyszewska-Podstawka A, PAWLAK D: *Not only immune escape - the confusing role of the TRP metabolic pathway in carcinogenesis*. **Cancers** 2021,13 (11), 26 doi: 10.3390/cancers13112667. PMID: 34071442

Mor A, Tankiewicz-Kwedło A, Krupa A, PAWLAK D: *Role of kynurenine pathway in oxidative stress during neurodegenerative disorders*.**Cells** 2021, 10 (7), 30 doi: 10.3390/cells10071603. PMID: 34206739

Sieklucka B, PAWLAK D, Domaniewski T, Hermanowicz J, Lipowicz P, Doroszko M, Pawlak K: *Serum PTH, PTH1R/ATF4 pathway, and the sRANKL/OPG system in bone as a new link between bone growth, cross-sectional geometry, and strength in young rats with experimental chronic kidney disease*. **Cytokine** 2021, 148, 9 doi: 10.1016/j.cyto.2021.155685. PMID: 34411988

Pawlak K, Sieklucka B, PAWLAK D: *Paracrine kynurenine pathway activation in the bone of young uremic rats can antagonize anabolic effects of PTH on bone turnover and strength through the disruption of PTH-dependent molecular signaling*. **International Journal of Molecular Sciences** 2021, 22 (12), 18 doi: 10.3390/ijms22126563. PMID: 34207309

Świętoń J, Mikłosz J, Shin-Ichi Y, Szczubiałka K, PAWLAK D, Mogielnicki A, Kańska B: *Reversal activity and toxicity of heparin-binding copolymer after subcutaneous administration of enoxaparin in mice*. **International Journal of Molecular Sciences** 2021, 22 (20), 14 doi: 10.3390/ijms222011149. PMID: 34681808

Kiluk M, Lewkowicz J, PAWLAK D, Tankiewicz-Kwedło A: *Crosstalk between tryptophan metabolism via kynurenine pathway and carbohydrate metabolism in the context of cardio-metabolic risk - review*. **Journal of Clinical Medicine** 2021, 10 (11), 20 doi: 10.3390/jcm10112484. PMID: 34199713

Hermanowicz J, Szymanowska A, Sieklucka B, Czarnomysy R, Pawlak K, Bielawska A, Bielawski K, Kalafut J, Przybyszewska A, Surażyński A, Rivero-Muller A, Mojzych M, PAWLAK D: *Exploration of novel heterofused 1,2,4-triazine derivative in colorectal cancer*. **Journal of Enzyme Inhibition and Medicinal Chemistry** 2021, 36, (1), 535-348 doi: 10.1080/14756366.2021.1879803. PMID: 33522320

Pawłowski T, PAWLAK D, Ingot M, Zalewska M, Marciniak D, Bugajska J, Janocha-Litwin J, Małyszczak K: *The role of anthranilic acid in the increase of depressive symptoms and major depressive disorder during treatment for hepatitis C with pegylated interferon- $\alpha$ 2a and oral ribavirin*. **Journal of Psychiatry and Neuroscience**. 2021, 46 (1), E166-E175 doi: 10.1503/jpn.190139. PMID: 33464780

Mor A, Tankiewicz-Kwedlo A, PAWLAK D: *Kynurenines as a novel target for the treatment of malignancies*. **Pharmaceutics** 2021, 14 (7), 26 doi: 10.3390/ph14070606. PMID: 34201791

Miklosz J, Kałaska B, Zajączkowski S, PAWLAK D, Mogielnicki A: *Monitoring of cardiorespiratory parameters in rats - validation based on pharmacological stimulation*. **Pharmaceutics** 2021, 14 (12), 15 doi: 10.3390/ph14121223. PMID: 34959624

Miklosz J, Kałaska B, Podlasz P, Chmielewska-Krzesińska M, Zajączkowski Miłosz, Kosiński A, PAWLAK D, Mogielnicki A: *Cardiovascular and respiratory toxicity of protamine sulfate in zebrafish and rodent models*. **Pharmaceutics** 2021, 13 (3), 23 doi: 10.3390/pharmaceutics13030359. PMID: 33803176

Hermanowicz J, Kałaska B, Pawlak K, Sieklucka B, Miklosz J, Mojzych M, PAWLAK D: *Preclinical toxicity and safety of MM-129 - first-in-class BTK/PD-L1 inhibitor as a potential candidate against colon cancer*. **Pharmaceutics** 2021, 13 (8), 19 doi: 10.3390/pharmaceutics13081222. PMID: 34452183

## 2020 rok

Różkiewicz D, Hermanowicz J, Tankiewicz-Kwedlo A, Sieklucka B, Pawlak K, Czarnomysy R, Bielawski K, Surażyński A, Kalafut J, Przybyszewska A, Koda M, Jakubowska K, Rivero-Muller A, PAWLAK D: *The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer*. **J Enz Inh Med Chem** 2020, 35(1), 1697-1711 doi: 10.1080/14756366.2020.1818738. PMID: 32912025

Hermanowicz J, Sieklucka B, Nosek K, PAWLAK D: *Intracellular mechanisms of tumor cells' immunoresistance*. **Acta Biochim Pol** 2020, 67(2), 143-148 doi: 10.18388/abp.2020\_2878. PMID: 32320192

Hermanowicz J, Kwiatkowska I, PAWLAK D: *Important players in carcinogenesis as potential targets in cancer therapy: an update*. **Oncotarget** 2020, 11(32), 3078-3101 doi: 10.18632/oncotarget.27689. PMID: 32850012

Mor A, Pawlak K, Kałaska B, Domaniewski T, Sieklucka B, Ziemińska M, Cylwik B, PAWLAK D: *Modulation of the paracrine kynurenic system in bone as a new regulator of osteoblastogenesis and bone mineral status in an animal model of chronic kidney disease treated with LP533401*. **Int J Mol Sci** 2020, 21, 17 doi: 10.3390/ijms21175979. PMID: 32825192

Karbowska M, Hermanowicz J, Tankiewicz-Kwedlo A, Kałaska B, Kamiński T, Nosek K, Wiśniewska R, PAWLAK D: *Neurobehavioral effects of uremic toxin-indoxyl sulfate in the rat model*. **Sci Rep** 2020, 10(1), 9483 doi: 10.1038/s41598-020-66421-y. PMID: 32528183

Kałaska B, Miklosz J, Kamiński K, Świętoń J, Jakimczuk A, Yusa Shin-Ichi, PAWLAK D, Nowakowska M, Szczubiałka K, Mogielnicki A: *Heparin-binding copolymer as a complete antidote for low-molecular-weight heparins in rats*. **J Pharmacol Exp Therap** 2020, 373(1), 51-61 doi: 10.1124/jpet.119.262931. PMID: 31937564

Mor A, Kałaska B, PAWLAK D: *Kynurenine pathway in chronic kidney disease: what's old, what's new, and what's next?* **Int J Trypt Res** 2020, 13, 18 doi:10.1177/1178646920954882

## 2019 rok

Miklosz J, Kałaska B, Kamiński K, Rusak M, Szczubiałka K, Nowakowska M, PAWLAK D, Mogielnicki A: *The inhibitory effect of protamine on platelets is attenuated by heparin without inducing thrombocytopenia in rodents*. **Marine Drugs** 2019, 17(9) 539 doi: 10.3390/md17090539. PMID: 31533230

PAWLAK D, Domaniewski T, Sieklucka B, Jakuć M, Pawlak K: *Inhibition of peripheral serotonin synthesis by LP533401 and disturbances in calcitropic hormones attenuated excessive osteoblastogenesis with simultaneous improvement of bone mineral status in 5/6 nephrectomized rats*. **Biochim Biophys Acta. Mol Basis Dis** 2019, 1865(11),165528 doi: 10.1016/j.bbadis.2019.08.004. PMID: 31398464

Leszczyńska A, Misztal T, Marcińczyk N, Kamiński T, Kramkowski K, Chabielska E, PAWLAK D.: *Effect of quinolinic acid - A uremic toxin from tryptophan metabolism - On hemostatic profile in rat and mouse thrombosis models*. **Adv Med Sci** 2019, 64(2), 370-380 doi: 10.1016/j.advms.2019.05.003. PMID: 31176868

PAWLAK D, Domaniewski T, Znorko B, Pawlak K: *The use of LP533401 as a therapeutic option for renal osteodystrophy affects, renal calcium handling, vitamin D metabolism, and bone health in uremic rats.* **Exp Opin Ther Targets** 2019, 23(4), 353-364 doi: 10.1080/14728222.2019.1586883. PMID: 30801205

Massalska M, Kuca-Warnawin E, Janicka I, Plebańczyk M, PAWLAK D, Dallos T, Olwert A, Radzikowska A, Małyk P, Kontny E, Maśliński W: *Survival of lymphocytes is not restricted by IDO-expressing fibroblast from rheumatoid arthritis patients.* **Immunopharmacol Immunotoxicol** 2019, 41(2), 214-223 doi: 10.1080/08923973.2019.1569048. PMID: 30714436

Kamiński T, Pawlak K, Karbowska M, Znorko B, Mor A, Myśliwiec M, PAWLAK D: *The impact of antihypertensive pharmacotherapy on interplay between protein-bound uremic toxin (indoxyl sulfate) and markers of inflammation in patients with chronic kidney disease.* **Int Urol Nephrol** 2019, 51(3), 491-502 doi: 10.1007/s11255-018-02064-3. PMID: 30617956

Rudzki L, Ostrowska L, PAWLAK D, Małus A, Pawlak K, Waszkiewicz N, Szulc A: *Probiotic Lactobacillus Plantarum 299v decreases kynurenine concentration and improves cognitive functions in patients with major depression: A double-blind, randomized, placebo controlled study.* **Psychoneuroendocrinology** 2019, 100, 213-222 doi: 10.1016/j.psyneuen.2018.10.010. PMID: 30388595

Leszczyńska A, Kamiński T, Misztal T, PAWLAK D: *Quinolinic acid does not influence coagulation profile, nor fibrinolytic activity, under physiological conditions in rats.* **Acta Pol Pharmac - Drug Res** 2019, 76(5), 863-871 doi: 10.32383/appdr/109409

Kałaska B, Mikłosz J, Kamiński K, Musielak B, Yusa Shin-Ichi, PAWLAK D, Nowakowska M, Szczubiałka K, Mogielnicki A: *The neutralization of heparan sulfate by heparin-binding copolymer as a potential therapeutic target.* **RSC Advances** 2019, 9(6), 3020-3029 doi: 10.1039/c8ra09724k

## 2018 rok

PAWLAK D, Znorko B, Kalaska B, Domaniewski T, Zawadzki R, Lipowicz P, Doroszko M, Łebkowska U, Grabowski P, Pawlak K: *LP533401 restores bone health in 5/6 nephrectomized rats by a decrease of gut-derived serotonin and regulation of serum phosphate through the inhibition of phosphate co-transporters expression in the kidneys.* **Bone** 2018, 113:124-136. doi: 10.1016/j.bone.2018.05.022. PubMed PMID: 29792935

Kalaska B, Kamiński K, Mikłosz J, Nakai K, Yusa SI, PAWLAK D, Nowakowska M, Mogielnicki A, Szczubiałka K: *Anticoagulant Properties of Poly(sodium 2-(acrylamido)-2-methylpropanesulfonate)-Based Di- and Triblock Polymers.* **Biomacromolecules** 2018, doi: 10.1021/acs.biomac.8b00691. PubMed PMID: 29733637

Znorko B, PAWLAK D, Oksztulska-Kolanek E, Domaniewski T, Pryczynicz A, Roszczenko A, Rogalska J, Lipowicz P, Doroszko M, Brzoska MM, Pawlak K: *RANKL/OPG system regulation by endogenous PTH and PTH1R/ATF4 axis in bone: Implications for bone accrual and strength in growing rats with mild uremia.* **Cytokine** 2018, 106:19-28. doi: 10.1016/j.cyto.2018.03.002. Epub 2018 Mar 9. PubMed PMID: 29529595

Tankiewicz-Kwedlo A, Hermanowicz JM, Domaniewski T, Pawlak K, Rusak M, Pryczynicz A, Surazynski A, Kaminski T, Kazberuk A, PAWLAK D: *Simultaneous use of erythropoietin and LFM-A13 as a new therapeutic approach for colorectal cancer.* **Br J Pharmacol** 2018, 175(5):743-762. doi: 10.1111/bph.14099. PubMed PMID: 29160911

Kaminski TW, Pawlak K, Karbowska M, Mysliwiec M, Grzegorzewski W, Kuna J, PAWLAK D: *Association between uremic toxin-anthranilic acid and fibrinolytic system activity in predialysis patients at different stages of chronic kidney disease.* **Int Urol Nephrol** 2018, 50(1):127-135. doi: 10.1007/s11255-017-1729-1. PubMed PMID: 29058166

Karbowska M, Kamiński T, Znorko B, Domaniewski T, Misztal T, Rusak T, Pryczynicz A, Guzińska-Ustymowicz K, Pawlak K, PAWLAK D: *Indoxyl sulfate promotes arterial thrombosis in rat model via increased levels of complex TF/VII, PAI-1, platelet activation as well as decreased contents of SIRT1 and SIRT3.* **Front Physiology** 2018, 9, 1623 doi: 10.3389/fphys.2018.01623. eCollection 2018. PMID: 30546314

Tankiewicz-Kwedlo A, Hermanowicz J, Pawlak K, Czarnomysy R, Bielawski K, Prokop, PAWLAK D.: *Erythropoietin intensifies the proapoptotic activity of LFM-A13 in cells and in a mouse model of colorectal cancer.* **Int J Mol Sci** 2018, 19(4), 1262, 17 doi: 10.3390/ijms19041262. PMID: 29690619

Mor A, Kamiński T, Karbowska M, PAWLAK D: *New insight into organic anion transporters from the perspective of potentially important interactions and drugs toxicity.* **J Physiol Pharmacol** 2018, 69(3), 307-324  
doi: 10.26402/jpp.2018.3.01. PMID: 30149367

Pawłowski T, Małyszczak K, Ingot M, Zalewska M, Radkowski M, Laskus T, PAWLAK D: *Alterations in the metabolism of tryptophan in patients with chronic hepatitis C six months after pegylated interferon-alpha 2a treatment.* **Psychoneuroendocrinology** 2018, 97, 1-7  
doi: 10.1016/j.psyneuen.2018.06.004. PMID: 29990677

Buczko P, Pawlak D, Kasacka I: *An important pathway of apoptotic effect of nickel early released from orthodontic appliances preliminary data.* **Pharmacol Rep** 2018, 70(4), 766-768  
doi: 10.1016/j.pharep.2018.02.019. PMID: 29936364

## 2017 rok

Kalaska B, Pawlak K, Domaniewski T, Oksztulska-Kolanek E, Znorko B, Roszczenko A, Rogalska J, Brzoska MM, Lipowicz P, Doroszko M, Pryczynicz A, PAWLAK D: *Elevated Levels of Peripheral Kynurenine Decrease Bone Strength in Rats with Chronic Kidney Disease.* **Front Physiol** 2017, 8, 836  
doi: 10.3389/fphys.2017.00836. eCollection 2017. PubMed PMID: 29163188

PAWLAK D, Domaniewski T, Znorko B, Oksztulska-Kolanek E, Lipowicz P, Doroszko M, Karbowska M, Pawlak K: *The impact of peripheral serotonin on leptin-brain serotonin axis, bone metabolism and strength in growing rats with experimental chronic kidney disease.* **Bone** 2017, 105, 1-10  
doi: 10.1016/j.bone.2017.08.004. PubMed PMID: 28797891

Kamiński T, Michałowska M, PAWLAK D: *Aryl hydrocarbon receptor (AhR) and its endogenous agonist - indoxyl sulfate in chronic kidney disease.* **Postepy Hig Med Dosw** 2017, 71, 624-632. PubMed PMID: 28791957

Karbowska M, Kaminski TW, Marcinczyk N, Misztal T, Rusak T, Smyk L, PAWLAK D: *The Uremic Toxin Indoxyl Sulfate Accelerates Thrombotic Response after Vascular Injury in Animal Models.* **Toxins** 2017, 9(7), E229.  
doi: 10.3390/toxins9070229. PubMed PMID: 28753957

Rudzki L, PAWLAK D, Pawlak K, Waszkiewicz N, Małus A, Konarzewska B, Gałęcka M, Bartnicka A, Ostrowska L, Szulc A: *Immune suppression of IgG response against dairy proteins in major depression.* **BMC Psychiatry** 2017, 17(1), 268 doi: 10.1186/s12888-017-1431-y. PubMed PMID: 28738849

Kalaska B, Pawlak K, Oksztulska-Kolanek E, Domaniewski T, Znorko B, Karbowska M, Citkowska A, Rogalska J, Roszczenko A, Brzoska MM, PAWLAK D: *A link between central kynurenine metabolism and bone strength in rats with chronic kidney disease.* **PeerJ** 2017, 20(5), e3199. doi: 10.7717/peerj.3199

Bartosiewicz J, Kaminski T, Pawlak K, Karbowska M, Tankiewicz-Kwedlo A, PAWLAK D: *The activation of the kynurenine pathway in a rat model with renovascular hypertension.* **Exp Biol Med** 2017, 242(7), 750-761  
doi: 10.1177/1535370217693114

Kamiński TW, Pawlak K, Karbowska M, Myśliwiec M, PAWLAK D: *Indoxyl sulfate - the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease.* **BMC Nephrol** 2017, 18(1), 35 doi: 10.1186/s12882-017-0457-1

## 2016 rok

PAWLAK D, Oksztulska-Kolanek E, Znorko B, Domaniewski T, Rogalska J, Roszczenko A, Brzoska MM, Pryczynicz A, Kemon A, Pawlak K.: *The association between elevated levels of peripheral serotonin and its Metabolite - 5-Hydroxyindoleacetic Acid and Bone Strength and Metabolism in Growing Rats with Mild experimental chronic kidney disease.* **PLoS One.** 2016, 11(10):e0163526 doi: 10.1371/journal.pone.0163526.

Frydecka D, Pawłowski T, PAWLAK D, Małyszczak K: *Functional Polymorphism in the Interleukin 6 (IL6) Gene with Respect to Depression Induced in the Course of Interferon- $\alpha$  and Ribavirin Treatment in Chronic Hepatitis Patients.* **Arch Immunol Ther Exp** 2016, 64, 169-175 doi: 10.1007/s00005-016-0441-7.

Kalaska B, Ciborowski M, Domaniewski T, Czyżewska U, Godzien J, Milyk W, Kretowski A, PAWLAK D.: *Serum metabolic fingerprinting after exposure of rats to quinolinic acid.* **J Pharm Biomed Anal.** 2016, 131, 175-182  
doi: 10.1016/j.jpba.2016.08.024.

Tankiewicz-Kwedlo A, Hermanowicz J, Surazynski A, Rozkiewicz D, Pryczynicz A, Domaniewski T, Pawlak K, Kemona A, PAWLAK D.: *Erythropoietin accelerates tumor growth through increase of erythropoietin receptor (EpoR) as well as by the stimulation of angiogenesis in DLD-1 and Ht-29 xenografts.* **Mol Cell Biochem.** 2016, 421(1-2):1-18. doi: 10.1007/s11010-016-2779-x.

Jasiewicz M., Moniuszko M., PAWLAK D., Knapp M., Rusak M., Kazimierczyk R., Musial W.J., Dabrowska M, Kaminski K.A.: *Activity of the kynurenine pathway and its interplay with immunity in patients with pulmonary arterial hypertension.* **Heart** 2016, 102(3), 230-237,

Kalaska B, Kaminski K, Miklosz J, Yusa SI, Sokolowska E, Blazejczyk A, Wietrzyk J, Kasacka I, Szczubialka K, PAWLAK D, Nowakowska M, Mogielnicki A.: *Heparin-binding copolymer reverses effects of unfractionated heparin, enoxaparin, and fondaparinux in rats and mice.* **Transl. Res.** 2016, 5  
doi: 10.1016/j.trsl.2016.06.009. PMID: 27456749

Sokolowska E, Kalaska B, Kaminski K, Lewandowska A, Blazejczyk A, Wietrzyk J, Kasacka I, Szczubialka K, PAWLAK D, Nowakowska M, Mogielnicki A. *The toxicokinetic profile of Dex40-GTMAC3-a novel polysaccharide candidate for reversal of unfractionated heparin.* **Front. Pharmacol.** 2016, 17(7), 60  
doi:10.3389/fphar.2016.00060

Karbowska M, Kamiński T, PAWLAK D.: *Methods of reducing the level of indoxyl sulfate - one of the most potent protein-bound uremic toxins.* **Toxin Reviews** 2016, 1-9 doi: 10.1080/15569543.2016.1222442

## 2015 rok

Michalowska M., Znorko B., Kaminski T., Oksztulska-Kolanek E., PAWLAK D.: *New insights into tryptophan and its metabolites in the regulation of bone metabolism.* **J. Physiol. Pharmacol.** 66(6), 779-791, 2015

Pawlak K., Mysliwiec M., PAWLAK D.: *Endocan-the new endothelial activation marker independently associated with soluble endothelial adhesion molecules in uraemic patients with cardiovascular disease.* **Clin. Biochem.** 48(6), 425-430, 2015

Michałowska. M, Znorko B., Oksztulska-Kolanek E., Kamiński T., PAWLAK D.: *A view at monoclonal antibodies in therapy of osteoporosis.* **Pol. Annals Med.** 22(2), 149-154, 2015

Kałaska B., Kamiński K., Sokółowska E., Czaplicki D., Kujdowicz M., Stalińska K., Bereta J., Szczubiałka K., PAWLAK D., Nowakowska M., Mogielnicki A.: *Nonclinical evaluation of novel cationically modified polysaccharide antidotes for unfractionated heparin.* **PLoS ONE** 10, 3, 2015 e0119486

Kamiński T., PAWLAK D.: *Leki generyczne we współczesnej farmakoterapii.* **Farm. Pol.** 70(6), 321-326, 2014

## 2014 rok

Pawlak K., Mysliwiec M., PAWLAK D.: *oxLDL - the molecule linking hypercoagulability with the presence of cardiovascular disease in hemodialyzed uraemic patients.* **Thromb. Res.** 134(3), 711-716, 2014

Pawlak K., Myśliwiec M., PAWLAK D.: *Effect of diabetes and oxidative stress on plasma CCL23 levels in patients with severe chronic kidney disease.* **Pol. Arch. Med. Wewn.** 124(9), 459-466, 2014

## 2013 rok

Pawlak K., Mysliwiec M., PAWLAK D.: *Oxidized low-density lipoprotein (oxLDL) plasma levels and oxLDL to LDL ratio - are they real oxidative stress markers in dialyzed patients?* **Life Sci.** 92 (4-5), 253-258, 2013

Pawlak K., Rozkiewicz D., Mysliwiec M., PAWLAK D.: *YKL-40 in hemodialyzed patients with and without cardiovascular complications - The enhancement by the coexistence of the seropositivity against hepatitis C virus infection.* **Cytokine** 62 (1), 75 -80, 2013

## 2012 rok

Pawlak K, Mysliwiec M, PAWLAK D.: *Oxidized LDL to autoantibodies against oxLDL ratio - the new biomarker associated with carotid atherosclerosis and cardiovascular complications in dialyzed patients.* **Atherosclerosis** 224 (1), 252-257, 2012

Pawlak K, Mysliwiec M, PAWLAK D.: *Hyperhomocysteinemia and the presence of cardiovascular disease are associated with kynurenic acid levels and carotid atherosclerosis in patients undergoing continuous ambulatory peritoneal dialysis.* **Thromb. Res.** 129 (6), 704-709, 2012

Pawlak K, Mysliwiec M, PAWLAK D.: *The alteration in Cu/Zn superoxide dismutase and adhesion molecules concentrations in diabetic patients with chronic kidney disease: the effect of dialysis treatment.* **Diabet. Res. Clin. Pract.** 98, 264-270, 2012

Pawlak K, Ulazka B., Mysliwiec M, PAWLAK D.: *Vascular endothelial growth factor and uPA/suPAR system in early and advanced chronic kidney disease patients: a new link between angiogenesis and hyperfibrinolysis?* **Translat. Res.** 160 (5), 346-354, 2012

## 2011 rok

Pawlak K, Mysliwiec M, PAWLAK D.: *Peripheral blood level alterations of MMP-2 and MMP-9 in patients with chronic kidney disease on conservative treatment and on hemodialysis.* **Clin. Biochem.** 44, 838-843, 2011

Pawlak K, Mysliwiec M, PAWLAK D.: *Interleukin-21 in hemodialyzed patients: Association with the etiology of chronic kidney disease and the seropositivity against hepatitis C virus infection.* **Clin. Biochem.** 44, 1416-1420, 2011

## 2010 rok

Pawlak K., Mysliwiec M., PAWLAK D.: *Kynurenine pathway - a new link between endothelial dysfunction and carotid atherosclerosis in chronic kidney disease patients.* **Adv. Med. Sci.** 55(2), 196-203, 2010

Pawlak K., Tankiewicz J., Mysliwiec M., PAWLAK D.: *Systemic Levels of MMP2/TIMP2 and Cardiovascular Risk in CAPD Patients.* **Nephron Clin. Pract.** 115(4), c251-c258, 2010

Pawlak K., Buraczewska-Buczko A., Mysliwiec M., PAWLAK D.: *Hyperfibrinolysis, uPA/suPAR system, kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on conservative treatment.* **Am. J. Med. Sci.** 339 (1), 5-9, 2010

Pawlak K., Mysliwiec M., PAWLAK D.: *Haemostatic system, biochemical profiles, kynurenines and the prevalence of cardiovascular disease in peritoneally dialyzed patients.* **Thromb. Res.** 125 (2), 40-45, 2010

Tankiewicz-Kwedlo A., PAWLAK D., Domaniewski T., Buczko W.: *Erythropoietin increases Epo and EpoR expression in DLD-1 cells.* **Pol. Ann. Med.** 17 (1), 16-24, 2010

Tankiewicz-Kwedlo A, PAWLAK D, Domaniewski T, Buczko W.: *Effect of erythropoietin, 5-fluorouracil and SN-38 on the growth of DLD-1 cells.* **Pharmacol. Rep.** 62(5), 926-937, 2010

Pawlak K, Mysliwiec M, PAWLAK D.: *Impact of residual renal function and HCV seropositivity on plasma CD40/CD40L system and oxidative status in haemodialysis patients.* **Clin. Biochem.** 43 (18), 1393-1398, 2010

Pawlak K, Mysliwiec M, PAWLAK D.: *Hepatitis C virus seropositivity and TNF superfamily receptors: sCD40, sFas--the new putative determinants of endothelial dysfunction in haemodialysis patients.* **Thromb. Res.** 126 (5), 393-398, 2010

Gulaj E, Pawlak K, Bien B, PAWLAK D.: *Kynurenine and its metabolites In Alzheimer's disease patients.* **Adv. Med. Sci.** 55(2), 204-211, 2010

Pawlak K, Kowalewska A, Mysliwiec M, PAWLAK D.: *3-hydroxyanthranilic acid is independently associated with monocyte chemoattractant protein-1 (CCL2) and macrophage inflammatory protein-1beta (CCL4) in patients with chronic kidney disease.* **Clin. Biochem.** 43 (13-14), 1101-1106, 2010

## 2009 rok

Pawlak K., Kowalewska A., Mysliwiec M., PAWLAK D.: *Kynurenine and its metabolites-kynurenic acid and anthranilic acid are associated with soluble endothelial adhesion molecules and oxidative status in patients with chronic kidney disease.* **Am. J. Med. Sci.** 338 (4), 293-300, 2009

Buczko P., Szarmach I.J., Kasacka I., PAWLAK D.: *The concentration of 3-HKYN in saliva of patients with fixed orthodontic appliances.* **Pol. J. Environ. Stud.** 18, 128-131, 2009



Pawlak K, Domaniewski T, Mysliwiec M, PAWLAK D. *Kynurenines and oxidative status are independently associated with thrombomodulin and von Willebrand factor levels in patients with end-stage renal disease.* **Thromb. Res.** 124 (4), 452-457, 2009

Pawlak K., Brzosko S., Mysliwiec M., PAWLAK D.: *Kynurenine, quinolinic acid-the new factors linked to carotid atherosclerosis in patients with end-stage renal disease.* **Atherosclerosis** 204 (2), 561-566, 2009

Pawlak K., Domaniewski T., Mysliwiec M., PAWLAK D.: *The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease.* **Atherosclerosis.** 204 (1), 309-314, 2009

Pawlak K., Mysliwiec M., PAWLAK D.: *Hypercoagulability is independently associated with kynurenine pathway activation in dialysed uraemic patients.* **Thromb. Haemost.** 102 (1), 49-55, 2009

Pawlak K., Tankiewicz J., Mysliwiec M., PAWLAK D.: *Tissue factor/its pathway inhibitor system and kynurenines in chronic kidney disease patients on conservative treatment.* **Blood Coagul. Fibrinolysis** 20, 590-594, 2009

Myśliwiec P., Myśliwiec H., PAWLAK D., Pawlak K., Buczek W., Baltaziak M., Dadan J.: *Tryptophan metabolism in experimental necrotizing acute pancreatitis.* **Folia Histochemica et Cytobiologica** 47, 231-236, 2009

Myśliwiec P., Myśliwiec H., PAWLAK D., Dadan J., Buczek W., Pawlak K.: *Tryptophan and its metabolites in renal allograft recipients.* **Przeegl. Lek.** 66 (3), 115-118, 2009

## 2008 rok

Pawlak K., PAWLAK D., Myśliwiec M.: *Urokinase-type plasminogen activator and metalloproteinase-2 are independently related to the carotid atherosclerosis in haemodialysis patients.* **Thromb. Res.** 121 (4), 543-548, 2008

Myśliwiec H., PAWLAK D., Flisiak I., Myśliwiec P., Myśliwiec M., Chodyncka B.: *Wybrane metabolity kinureny a świąd mocznicowy.* **Przeegl. Dermatol.** 95 (1), 33-36, 2008

Pawlak K., PAWLAK D., Mysliwiec M.: *Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients.* **Thromb. Res.** 121 (6), 787-791, 2008

Pawlak K., Mysliwiec M., PAWLAK D.: *The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients.* **Thromb. Res.** 122, 328-335, 2008

Pawlak J., Dziecioł J., Mantur M., PAWLAK D.: *Megakaryocytes and platelets in experimentally induced renovascular hypertension (2K1C) in rats = Megakariocyty i płytki w doświadczalnym nadciśnieniu naczyniowo-nerkowym (2K1C) u szczurów.* **Post. Hig. Med. Doświad.** 62, 241-248, 2008

Pawlak K., Mysliwiec M., PAWLAK D.: *Oxidative stress, phosphate and creatinine levels are independently associated with vascular endothelial growth factor levels in patients with chronic renal failure.* **Cytokine** 43, 98-101, 2008

Pawlak K., Zolbach K., Borawski J., Mysliwiec M., Kovalchuk O., Chyczewski L., PAWLAK D.: *Chronic viral hepatitis C, oxidative stress and the coagulation/fibrinolysis system in haemodialysis patients.* **Thromb. Res.** 123 (1), 166-170, 2008

## 2007 rok

Gułaj E., PAWLAK D.: *Niedokrwistość.* **Farm. Pol.** 63 (1), 3-10, 2007

Pawlak K., PAWLAK D.: *Placebo niedowartościowana psychoterapia?* **Gazeta Farmaceutyczna** 4, 46-49, 2007

Pawlak K., PAWLAK D., Mysliwiec M.: *Impaired renal function and duration of dialysis therapy are associated with oxidative stress and proatherogenic cytokine levels in patients with end-stage renal disease.* **Clin. Biochem.** 40 (1-2), 81-85, 2007

Pawlak K., PAWLAK D., Mysliwiec M.: *Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity.* **Thromb. Res.** 119 (4), 475-480, 2007

Pawlak K., PAWLAK D., Mysliwiec M.: *Serum matrix metalloproteinase-2 and increased oxidative stress are associated with carotid atherosclerosis in hemodialyzed patients.* **Atherosclerosis** 190 (1), 199-204, 2007

Pawlak K., PAWLAK D., Mysliwiec M.: *Long-term erythropoietin therapy does not affect endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients.* **Thromb. Res.** 120 (6), 797-803, 2007

Pawlak K., PAWLAK D., Mysliwiec M.: *Long-term erythropoietin therapy does not affect metalloproteinases and their inhibitor levels, oxidative stress and inflammation in hemodialyzed patients.* **Am. J. Nephrol.** 27 (3), 221-225, 2007

Pawlak K., PAWLAK D., Mysliwiec M.: *Tissue factor and urokinase-type plasminogen activator system are related to the presence of cardiovascular disease in hemodialysis patients.* **Thromb. Res.** 120 (6), 871-876, 2007

Pawlak K., Mysliwiec M., PAWLAK D.: *Chronic viral hepatitis and iron affect the plasma levels of LIGHT--a new member of the TNF superfamily in uraemic haemodialyzed patients.* **Cytokine** 39 (3), 201-206, 2007

Pawlak K., PAWLAK D., Mysliwiec M.: *LIGHT- a new member of the TNF superfamily in the plasma, dialysate and urine of uremic patients; the impact of residual diuresis and presence of viral hepatitis.* **Clin. Biochem.** 40 (16-17), 1240-1244, 2007

Buczko P., Tankiewicz-Kwedlo A., Buraczewska A., Myśliwiec M., PAWLAK D.: *Accumulation of kynurenine pathway metabolites in saliva and plasma of uremic patients.* **Pharmacol. Rep.** 59 (1), 199-204, 2007

Szarmach I., Buczko P., Tankiewicz-Kwedlo A., Kasacka I., Tankiewicz J., PAWLAK D.: *The concentration of kynurenine and anthranilic acid in saliva of patients with fixed orthodontic appliances.* **Pol. J. Environ. Stud.** 16 (2), 125-127, 2007

Tankiewicz-Kwedlo A., Buczko P., Dziemiańczyk-Pakiela D., Szarmach I., Grabowska S., Topczewska-Bruns J., PAWLAK D.: *Tryptophan metabolism in patients with oral squamous cell carcinoma.* **Pol. J. Environ. Stud.** 16 (2), 120-124, 2007

Pawlak K., PAWLAK D., Mysliwiec M.: *Erythropoietin therapy decreased tissue factor, its pathway inhibitor, and oxidative stress in peritoneal dialysis patients with diabetes.* **Nephron Clin. Pract.** 107 (1), c20-c25, 2007

Pawlak K., PAWLAK D., Mysliwiec M.: *Association between tissue factor, its pathway inhibitor and oxidative stress in peritoneal dialysis patients.* **Blood Coagul. Fibrinolysis** 18 (5), 467-471, 2007

## 2006 rok

Langfort J., Barańczuk E., PAWLAK D., Chalimoniuk M., Lukacova N., Marsala J., Górski J.: *The effect of endurance training on regional serotonin metabolism in the brain during early stage of detraining period in the female rat.* **Cell Mol. Neurobiol.** 26 (7-8), 1327-1342, 2006

Buczko P., Stokowska W., Górka M., Kucharewicz I., PAWLAK D., Buczko W.: *Tryptophan metabolites via kynurenine pathway in saliva of diabetic patients.* **Dent. Med. Problems** 43 (1), 21-25, 2006

## 2005 rok

Tankiewicz A., PAWLAK D., Pawlak K., Szewc D., Myśliwiec M., Buczko W.: *Anthranilic acid-uraemic toxin damaged red cell's membrane.* **Int. Urol. Nephrol.** 37 (3), 621-627, 2005

PAWLAK D., Brzóska M., Zwierz K., Stypułkowska A., Moniuszko-Jakoniuk J.: *Can kynurenine pathway tryptophan metabolites be used to monitor cadmium exposure?* **Pol. J. Environ. Stud.** 14 (2), 209-215, 2005

PAWLAK D., Brzóska M., Moniuszko-Jakoniuk J., Stypułkowska A., Zwierz K.: *Effect of cadmium on the peripheral kynurenine pathway in rats.* **Pol. J. Environ. Stud.** 14 (4), 501-507, 2005

Pawlak K., PAWLAK D., Myśliwiec M.: *Metoda terapii nerkozastępczej a wybrane wskaźniki stresu oksydacyjnego i uszkodzenia śródbłonna u pacjentów z przewlekłą niewydolnością nerek.* **Pol. Arch. Med. Wewn.** 113 (1), 21-26, 2005

Pawlak K., PAWLAK D., Mysliwiec M.: *Cu/Zn superoxide dismutase plasma levels as a new useful clinical biomarker of oxidative stress in patients with end-stage renal disease.* **Clin. Biochem.** 38 (8), 700-705, 2005

Pawlak K., PAWLAK D., Mysliwiec M.: *Circulating beta-chemokines and matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system in hemodialyzed patients--role of oxidative stress.* **Cytokine** 31 (1), 18-24, 2005

## 2004 rok

Pawlak K., Naumnik B., Brzóska S., PAWLAK D., Myśliwiec M.: *Oxidative stress - a link between endothelial injury, coagulation activation, and atherosclerosis in haemodialysis patients.* **Am. J. Nephrol.** 24 (1), 154-161, 2004

Pawlak K., PAWLAK D., Mysliwiec M.: *Hepatitis intensified oxidative stress, MIP-1beta and RANTES plasma levels in uraemic patients.* **Cytokine** 28 (6), 197-204, 2004

Pawlak K., PAWLAK D., Mysliwiec M.: *Extrinsic coagulation pathway activation and metalloproteinase-2/TIMPs system are related to oxidative stress and atherosclerosis in hemodialysis patients.* **Thromb. Haemost.** 92 (3), 646-653, 2004

Pawlak S., PAWLAK D., Buczko W.: *Wpływ hipoksji na regulację procesu erytropoezy - nowe spojrzenie.* **Przeg. Lek.** 61 (12), 1415-1419, 2004

Pawlak K., PAWLAK D., Mysliwiec M.: *Possible new role of monocyte chemoattractant protein-1 in hemodialysis patients with cardiovascular disease.* **Am. J. Nephrol.** 24 (6), 635-640, 2004

Pawlak K., PAWLAK D., Mysliwiec M.: *Oxidative stress influences CC-chemokine levels in hemodialyzed patients.* **Nephron Physiol.** 96 (4), 105-112, 2004

## 2003 rok

Tankiewicz A., PAWLAK D., Topczewska-Bruns J., Buczko W.: *Kidney and liver kynurenine pathway enzymes in chronic renal failure.* **Adv. Exp. Med. Biol.** 527, 409-414, 2003

PAWLAK D., Koda M., Wołczyński S., Myśliwiec M., Buczko W.: *Mechanism of inhibitory effect of 3-hydroxykynurenine on erythropoiesis in patients with renal insufficiency.* **Adv. Exp. Med. Biol.** 527, 375-380, 2003

Topczewska-Bruns J., PAWLAK D., Tankiewicz A., Chabielska E., Buczko W.: *Kynurenine metabolism in central nervous system in experimental chronic renal failure.* **Adv. Exp. Med. Biol.** 527, 177-182, 2003

PAWLAK D., Tankiewicz A., Matys T., Buczko W.: *Peripheral distribution of kynurenine metabolites and activity of kynurenine pathway enzymes in renal failure.* **J. Physiol. Pharmacol.** 54, 175-189, 2003

PAWLAK D., Koda M., Pawlak S., Wołczyński S., Buczko W.: *Contribution of quinolinic acid in the development of anemia in renal insufficiency.* **Am. J. Physiol. Renal Physiol.** 284, F693-700, 2003

## 2002 rok

Topczewska-Bruns J., PAWLAK D., Chabielska E., Tankiewicz A., Buczko W.: *Increased levels of 3-hydroxykynurenine in different brain regions of rats with chronic renal insufficiency.* **Brain Res. Bull.** 58, 423-428, 2002

Kucharewicz I., Pawlak R., Matys T., PAWLAK D., Buczko W.: *Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7).* **Hypertension** 40, 774-779, 2002

PAWLAK D., Tankiewicz A., Myśliwiec P., Buczko W.: *Tryptophan metabolism via the kynurenine pathway in experimental chronic renal failure.* **Nephron** 90, 328-335, 2002

Myśliwiec P., PAWLAK D., Myśliwiec M., Buczko W.: *Endogenous neurotoxicine - quinolinic acid is increased in renal allograft recipients.* **Transp. Proc.** 34, 598-600, 2002

Topczewska-Bruns J., PAWLAK D., Buczko W.: *Modyfikacje szlaku kinureninowego – nowe możliwości leczenia chorób OUN?* **Farm. Pol.** 2, 51-56, 2002

## 2001 rok

Andrzejewska-Buczko J., PAWLAK D., Tankiewicz A., Matys T., Buczko W.: Possible involvement of kynurenamines in the pathogenesis of cataract in diabetic patients. **Med. Sci. Monit.** 7, 742-745, 2001

Topczewska-Bruns J., Tankiewicz A., PAWLAK D., Buczko W.: *Behavioral changes in the course of chronic renal insufficiency in rats.* **Pol. J. Pharmacol.** 53, 263-269, 2001

PAWLAK D., Tankiewicz A., Buczko W.: *Kynurenine and its metabolites in the rat with experimental renal insufficiency.* **J. Physiol. Pharmacol.** 52, 755-766, 2001

PAWLAK D., Pawlak K., Małyszko J., Myśliwiec M., Buczko W.: *Accumulation of toxic products degradation of kynurenine in hemodialyzed patients.* **Int. Urol. Nephrol.** 33, 399-404, 2001

Tankiewicz A., PAWLAK D., Buczko W.: *Enzymy szlaku kinureninowego.* **Post. Hig. Med. Dośw.** 55, 715-731, 2001

## 2000 rok

Małyszko J.S., Małyszko J., Pawlak K., PAWLAK D., Buczko W., Myśliwiec M.: *Importance of serotonergic mechanisms in the thrombotic complications in hemodialyzed patients treated with erythropoietin.* **Nephron** 84, 305-311, 2000

Małyszko J.S., PAWLAK D., Małyszko J., Buczko W., Myśliwiec M.: *Peripheral serotonergic system in hemodialyzed and peritoneally dialyzed patients.* **Nephron** 86, 396-397, 2000

PAWLAK D., Takada Y., Urano T., Takada A.: *Serotonergic and kynurenic pathways in rats exposed to foot shock.* **Brain Res. Bull.** 52, 197-205, 2000

PAWLAK D., Malczyk E., Darewicz J., Azzadin A., Buczko W.: *Platelet serotonergic mechanisms in patients with cancer of the urinary bladder.* **Thromb. Res.** 2000 98, 367-374, 2000

Chabielska E., Matys T., Kucharwicz I., PAWLAK D., Rólkowski R., Buczko W.: *The involvement of AT<sub>2</sub>-receptor in the antithrombotic effect of losartan in renal hypertensive rats.* **J. Renin Angiotensin Aldosterone Syst.** 1, 263-267, 2000

Kucharewicz I., Chabielska E., PAWLAK D., Matys T., Rólkowski R., Buczko W.: *The antithrombotic effect of angiotensin-(1-7) closely resembles that of losartan.* **J. Renin Angiotensin Aldosterone Syst.** 1, 268-272, 2000

Myśliwiec P., PAWLAK D.: *Szlak kinurenowy w zdrowiu i w chorobie.* **Post. Hig. Med. Dośw.** 54, 239-252, 2000

## 1999 rok

Siwak E.B., PAWLAK D., Buczko W., Kondrusiuk M., Hermanowska- Szpakowicz T.: *Stężenie serotoniny w płynie mózgowo-rdzeniowym w przebiegu ropnych i kleszczowych zapaleń opon mózgowo-rdzeniowych i mózgu.* **Neurol. Neurochir. Pol.** 33, 339-349, 1999

## 1998 rok

PAWLAK D., Adamkiewicz M., Małyszko J., Takada A., Myśliwiec M., Buczko W.: *Vascular and cardiac effects of DV-7028 - a selective, 5-HT<sub>2A</sub> receptor antagonist in rats.* **J. Cardiovasc. Pharmacol.** 32, 266-273, 1998

PAWLAK D., Pawlak K., Chabielska E., Małyszko J., Takada A., Myśliwiec M., Buczko W.: *DV-7028, a potent 5-hydroxytryptamine receptor (5-HT<sub>2A</sub>) antagonist delays arterial thrombosis development in rats.* **Thromb. Res.** 90, 259-270, 1998

Chabielska E., Pawlak R., Golatowski R., Rólkowski R., PAWLAK D., Buczko W.: *Losartan inhibits experimental venous thrombosis in spontaneously hypertensive rats.* **Thromb. Res.** 90, 271-278, 1998

Małyszko J.S., Małyszko J., PAWLAK D., Buczko W., Myśliwiec M.: *Hemostasis, platelet functions, serotonin and serum lipids during omega-3 fatty acid treatment in patients with glomerulonephritis.* **Nephron** 80, 94-96, 1998

Myśliwiec M., Małyszko J.S., Małyszko J., PAWLAK D., Buczko W.: *Peripheral serotonergic mechanisms in kidney diseases.* **Annal. Universit. M. Curie-Skłodowska Lublin-Polonia** LII, 9-16, 1998

## 1997 rok

Łukaszewicz A., Markowski T., PAWLAK D.: *Porównanie stężenia endogennego etanolu w surowicy krwi u alkoholików w różnym okresie abstynencji i u osób nie uzależnionych od alkoholu etylowego.* **Psychiatr. Pol.** 31, 183-188, 1997

Kowal-Bielecka O., Bernacka K., PAWLAK D., Buczek W.: *Serotonina a procesy immunologiczno-zapalne w reumatoidalnym zapaleniu stawów.* **Reumatologia** 35 (3), 329-338, 1997

Rydzewski A., Małyszko J., Borawski J., PAWLAK D., Azzadin A., Buczek W., Myśliwiec M.: *Altered circadian rhythm of platelet aggregation in hemodialyzed patients.* **Nephron** 77, 365-367, 1997

## 1996 rok

Małyszko J.S., Małyszko J., PAWLAK D., Pawlak K., Myśliwiec M., Rydzewski A., Buczek W.: *Comprehensive study on platelet function, hemostasis, fibrinolysis, peripheral serotonergic system and serum lipids in nephrotic syndrome.* **Pol. J. Pharmacol.** 48, 191-195, 1996

Małyszko J., PAWLAK D., Małyszko J.S., Pawlak K., Buczek W., Myśliwiec M.: *Platelet aggregation and peripheral serotonergic system in kidney transplant recipients treated with cyclosporine.* **Transplant. Proc.** 28, 1956-1959, 1996

PAWLAK D., Małyszko J., Małyszko J.S., Pawlak K., Buczek W., Myśliwiec M.: *Peripheral serotonergic system in uremia.* **Thromb. Res.** 83, 189-194, 1996

Małyszko J., Małyszko J.S., PAWLAK D., Pawlak K., Buczek W., Myśliwiec M.: *Hemostasis, platelet function and serotonin in acute and chronic renal failure.* **Thromb. Res.** 83, 351-361, 1996

Andrzejewska-Buczek J., PAWLAK D., Walkowiak M., Stankiewicz A.: *Serotonina w retinopatii cukrzycowej.* **Klin. Oczna** 98, 101-104, 1996

Telejko B., Kinalska I., PAWLAK D., Buczek W.: *Platelet serotonergic mechanisms in patients with diabetes mellitus and vascular complications.* **Pol. J. Endocrinol.** 47, 65-71, 1996

Krygicz D., Azzadin A., Pawlak R., Małyszko J.S., PAWLAK D., Myśliwiec M., Buczek W.: *Cyclosporine A affects serotonergic mechanisms in uremic rats.* **Pol. J. Pharmacol.** 48, 351-354, 1996

PAWLAK D., Małyszko J., Myśliwiec M., Takada A., Buczek W.: *Effect of DV-7028, a novel serotonin 5-HT<sub>2</sub> receptor antagonist on the cardiovascular system in rats.* **Acta Physiol. Hung.** 84, 325-326, 1996

PAWLAK D., Małyszko J., Myśliwiec M., Takada A., Buczek W.: *Influence of MCI-9042, a novel 5-HT<sub>2</sub> receptor blocker on blood vessels on the rat.* **Acta Physiol. Hung.** 84, 323-324, 1996

Filipowski T., PAWLAK D., Morełowska-Topczewska B., Buczek W.: *Peripheral serotonergic mechanisms in the cardiovascular system of epidermoid lung cancer patients.* **Acta Physiol. Hung.** 84, 193-194, 1996

PAWLAK D., Malinowska B., Wollny T., Godlewski G., Buczek W.: *Lack of the specific influence of histamine and histamine H<sub>1</sub>, H<sub>2</sub> and H<sub>3</sub> receptor ligands on the serotonin uptake and release in blood platelets.* **Pol. J. Pharmacol.** 48, 615-620, 1996

## 1995 rok

Morełowska-Spierzak D., PAWLAK D., Buczek W.: *Influence of captopril on the serotonin - induced vasopressor effect in tail artery isolated from two - kidney, one clip renal hypertensive rats.* **Pol. J. Pharmacol.** 47, 417-422, 1995

Di Girolamo M., Silletta M.G., De Matteis M.A., Braca A., Colnzi A., PAWLAK D., Rasenick M.M., Luini A., Corda D.: *Evidence that the 50 kDa substrate of brefeldin A - dependent ADP-ribosylation binds GTP and is modulated by the G - protein  $\beta\gamma$  subunit complex.* **P. Natl. Acad. Sci. USA** 92, 7065-7069, 1995

Małyszko J., Małyszko J.S., Myśliwiec M., PAWLAK D., Buczek W.: *Układ fibrynolizy i obwodowy układ serotonergiczny u chorych z kłębuszkowym zapaleniem nerek.* **Przegl. Lek.** 52, 428-430, 1995

### 1993 rok

PAWLAK D., Chabielska E., Buczek W.: *Influence of acetaldehyde on some serotonergic mechanisms in rat blood platelets.* **Pol. J. Pharmacol.** 45, 59-66, 1993

PAWLAK D., Morełowska-Spierzak D., Azzadin A., Wróbel K., Buczek W.: *Lack of effect of acetaldehyde on the cardiovascular system in rats.* **Alcohol Alcoholism** 28, 529-533, 1993

Buczek W., Malinowska B., Pietraszek M.H., PAWLAK D., Chabielska E.: *Influence of Tolpa preparation on haemostasis in rats.* **Acta Pol. Pharm. Drug Res.** 50, 507-511, 1993

Popławski A., Azzadin A., PAWLAK D., Buczek W., Kaliszewski Z.: *Hamowanie procesu erytropoezy przez ultrafiltrat uzyskany od chorych z krańcową niewydolnością nerek.* **Pol. Tyg. Lek.** 50, 334-337, 1993

### 1992 rok

PAWLAK D., Malinowska B., Buczek W.: *Cardiovascular effects of acetaldehyde in pithed rats.* **Pharmacology** 45, 83-89, 1992

Azzadin A., Białkowska A., PAWLAK D., Chabielska E., Mazerska M., Myśliwiec M., Buczek W.: *Serotonin is involved in some effects of erythropoietin.* **Thromb. Res.** 65, 657-661, 1992

Malinowska B., PAWLAK D., Buczek W.: *Influence of DAU 6215, a novel 5-HT<sub>3</sub> receptor antagonist on the cardiovascular system in anaesthetized and pithed rats.* **Agents Actions** 36, 230-236, 1992

PAWLAK D., Krygicz D., Chabielska E., Buczek W.: *Influence of acetaldehyde on vasopressor effect of serotonin in pithed rats.* **Alcohol Alcoholism** 27, 367-372, 1992

Buczek W., Malinowska B., Chabielska E., PAWLAK D.: *Effect of ethanol on blood serotonergic mechanisms.* **Hemostasis and Circulation** A. Takada, A.Z. Budzynski Eds, Springer-Verlag, Tokyo, Berlin, Heidelberg, New York, London, Paris, Hong Kong, Barcelona, 133-138, 1992

Morełowska D., Chabielska E., PAWLAK D., Azzadin A., Krygicz D., Buczek W.: *Effect of captopril on serotonergic mechanisms in two-kidney, one-clip renal hypertensive rats.* **Pol. J. Pharmacol.** 44, 365-372, 1992

### 1991 rok

Buczek W., Malinowska B., Chabielska E., PAWLAK D., Pietraszek M.: *Udział mechanizmów serotonergicznnych w działaniu alkoholu etylowego na układ krążenia szczura.* **Alkoholizm i Narkomania** 57-66, 1991

### 1990 rok

Malinowska B., Pietraszek M., Chabielska E., PAWLAK D., Buczek W.: *The effect of ethanol and serotonin on blood vessels of the rat.* **Pol. J. Pharmacol.** 42, 333-342, 1990

Malinowska B., PAWLAK D., Chabielska E., Buczek W.: *Influence of acute and chronic ethanol administration on the vasopressor effect of serotonin in pithed rats.* **Pharmacology** 41, 91-97, 1990

### 1989 rok

Malinowska B., PAWLAK D., Chabielska E., Buczek W.: *Cardiovascular effect of ethanol in anaesthetized, conscious and pithed rats.* **Drug Alcohol Depend.** 24, 51-56, 1989